Template:Parenteral potencies and durations of progestogens
Jump to navigation
Jump to search
Progestogen | Form | Major brand names | Class | TFD (14 days) |
POIC-D (2–3 months) |
CIC-D (month) |
Duration | |
---|---|---|---|---|---|---|---|---|
Algestone acetophenide | Oil solution | Perlutal, Topasel, Yectames | Pregnane | ? | – | 75–150 mg | 100 mg ≈ 14–32 days | |
Cyproterone acetate | Oil solution | Androcur Depot | Pregnane | ? | – | – | 300 mg ≈ 20 days | |
Dydrogesteronea | Aqueous suspension | – | Retropregnane | ? | – | – | 100 mg ≈ 16–38 days | |
Gestonorone caproate | Oil solution | Depostat, Primostat | Norpregnane | 25–50 mg | – | – | 25–50 mg ≈ 8–13 days | |
Hydroxyprogesterone acetatea | Aqueous suspension | – | Pregnane | 350 mg | – | – | 150–350 mg ≈ 9–16 days | |
Hydroxyprogesterone caproate | Oil solution | Delalutin, Proluton, Makena | Pregnane | 250–500 mgb | – | 250–500 mg | 65–500 mg ≈ 5–21 days | |
Levonorgestrel butanoatea | Aqueous suspension | – | Gonane | ? | – | – | 5–50 mg ≈ 3–6 months | |
Lynestrenol phenylpropionatea | Oil solution | – | Estrane | ? | – | – | 50–100 mg ≈ 14–30 days | |
Medroxyprogesterone acetate | Aqueous suspension | Depo-Provera | Pregnane | 50–100 mg | 150 mg | 25 mg | 50–150 mg ≈ 14–50+ days | |
Megestrol acetate | Aqueous suspension | Mego-E | Pregnane | ? | – | 25 mg | 25 mg ≈ >14 daysc | |
Norethisterone enanthate | Oil solution | Noristerat, Mesigyna | Estrane | 100–200 mg | 200 mg | 50 mg | 50–200 mg ≈ 11–52 days | |
Oxogestone phenylpropionatea | Oil solution | – | Norpregnane | ? | – | – | 100 mg ≈ 19–20 days | |
Progesterone | Oil solution | Progestaject, Gestone, Strone | Pregnane | 200 mgb | – | – | 25–350 mg ≈ 2–6 days | |
Aqueous suspension | Agolutin Depot | Pregnane | 50–200 mg | – | – | 50–300 mg ≈ 7–14 days | ||
Note: All by intramuscular or subcutaneous injection. All are synthetic except for P4, which is bioidentical. P4 production during the luteal phase is ~25 (15–50) mg/day. The OID of OHPC is 250 to 500 mg/month. Footnotes: a = Never marketed by this route. b = In divided doses (2 × 125 or 250 mg for OHPC, 10 × 20 mg for P4). c = Half-life is ~14 days. Sources: Main: [1][2][3][4][5][6][7][8][9] Additional: [10][11][12][13][14][15][16][17][18][19][20] |
Template documentation
See also
- Template:Oral potencies of progestogens
- Template:Potencies and durations of natural estrogens by intramuscular injection
- Template:Parenteral durations of androgens/anabolic steroids
References
- ↑ Knörr, Karl; Beller, Fritz K.; Lauritzen, Christian (17 April 2013). Lehrbuch der Gynäkologie. Springer-Verlag. pp. 214–. ISBN 978-3-662-00942-0.
{{cite book}}
: Unknown parameter|name-list-format=
ignored (help) - ↑ Knörr, Karl; Knörr-Gärtner, Henriette; Beller, Fritz K.; Lauritzen, Christian (8 March 2013). Geburtshilfe und Gynäkologie: Physiologie und Pathologie der Reproduktion. Springer-Verlag. pp. 583–. ISBN 978-3-642-95583-9.
{{cite book}}
: Unknown parameter|name-list-format=
ignored (help) - ↑ A. Labhart (6 December 2012). Clinical Endocrinology: Theory and Practice. Springer Science & Business Media. pp. 554–. ISBN 978-3-642-96158-8.
- ↑ Horský, Jan; Presl, Jiří (1981). "Hormonal Treatment of Disorders of the Menstrual Cycle". In J. Horsky; J. Presl (eds.). Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 309–332. doi:10.1007/978-94-009-8195-9_11. ISBN 978-94-009-8195-9.
- ↑ Joachim Ufer (1969). The Principles and Practice of Hormone Therapy in Gynaecology and Obstetrics. de Gruyter. p. 49.
17α-Hydroxyprogesterone caproate is a depot progestogen which is entirely free of side actions. The dose required to induce secretory changes in primed endometrium is about 250 mg. per menstrual cycle.
- ↑ Willibald Pschyrembel (1968). Praktische Gynäkologie: für Studierende und Ärzte. Walter de Gruyter. pp. 598, 601. ISBN 978-3-11-150424-7.
- ↑ Ferin J (September 1972). "Effects, Duration of Action and Metabolism in Man". In Tausk M (ed.). Pharmacology of the Endocrine System and Related Drugs: Progesterone, Progestational Drugs and Antifertility Agents. Vol. II. Pergamon Press. pp. 13–24. ISBN 978-0080168128. OCLC 278011135.
- ↑ Milan Rastislav Henzl; John A. Edwards (10 November 1999). "Pharmacology of Progestins: 17α-Hydroxyprogesterone Derivatives and Progestins of the First and Second Generation". In Régine Sitruk-Ware; Daniel R. Mishell (eds.). Progestins and Antiprogestins in Clinical Practice. Taylor & Francis. pp. 101–132. ISBN 978-0-8247-8291-7.
- ↑ Janet Brotherton (1976). Sex Hormone Pharmacology. Academic Press. p. 114. ISBN 978-0-12-137250-7.
- ↑ Sang GW (April 1994). "Pharmacodynamic effects of once-a-month combined injectable contraceptives". Contraception. 49 (4): 361–85. doi:10.1016/0010-7824(94)90033-7. PMID 8013220.
- ↑ Toppozada MK (April 1994). "Existing once-a-month combined injectable contraceptives". Contraception. 49 (4): 293–301. doi:10.1016/0010-7824(94)90029-9. PMID 8013216.
- ↑ Bagade O, Pawar V, Patel R, Patel B, Awasarkar V, Diwate S (2014). "Increasing use of long-acting reversible contraception: safe, reliable, and cost-effective birth control" (PDF). World J Pharm Pharm Sci. 3 (10): 364–392. ISSN 2278-4357.
- ↑ Goebelsmann U (1986). "Pharmacokinetics of Contraceptive Steroids in Humans". In Gregoire AT, Blye RP (eds.). Contraceptive Steroids: Pharmacology and Safety. Springer Science & Business Media. pp. 67–111. doi:10.1007/978-1-4613-2241-2_4. ISBN 978-1-4613-2241-2.
- ↑ Becker, H.; Düsterberg, B.; Klosterhalfen, H. (1980). "Bioverfügbarkeit von Cyproteronacetat nach oraler und intramuskulärer Applikation bei Männern" [Bioavailability of Cyproterone Acetate after Oral and Intramuscular Application in Men]. Urologia Internationalis. 35 (6): 381–385. doi:10.1159/000280353. ISSN 1423-0399.
- ↑ Moltz, L.; Haase, F.; Schwartz, U.; Hammerstein, J. (2008). "Die Behandlung androgenisierter Frauen mit intramuskulär applizierbarem Cyproteronacetat" [Efficacy of Intra muscularly Applied Cyproterone Acetate in Hyperandrogenism]. Geburtshilfe und Frauenheilkunde. 43 (05): 281–287. doi:10.1055/s-2008-1036893. ISSN 0016-5751.
- ↑ Jeremy C. Wright; Diane J. Burgess (29 January 2012). Long Acting Injections and Implants. Springer Science & Business Media. pp. 114–. ISBN 978-1-4614-0554-2.
- ↑ Chu YH, Li Q, Zhao ZF (April 1986). "Pharmacokinetics of megestrol acetate in women receiving IM injection of estradiol-megestrol long-acting injectable contraceptive". The Chinese Journal of Clinical Pharmacology.
The results showed that after injection the concentration of plasma MA increased rapidly. The meantime of peak plasma MA level was 3rd day, there was a linear relationship between log of plasma MA concentration and time (day) after administration in all subjects, elimination phase half-life t1/2β = 14.35 ± 9.1 days.
- ↑ Benno Clemens Runnebaum; Thomas Rabe; Ludwig Kiesel (6 December 2012). Female Contraception: Update and Trends. Springer Science & Business Media. pp. 429–. ISBN 978-3-642-73790-9.
- ↑ Paolo Giovanni Artini; Andrea R. Genazzani; Felice Petraglia (11 December 2001). Advances in Gynecological Endocrinology. CRC Press. pp. 105–. ISBN 978-1-84214-071-0.
- ↑ King TL, Brucker MC, Kriebs JM, Fahey JO (21 October 2013). Varney's Midwifery. Jones & Bartlett Publishers. pp. 495–. ISBN 978-1-284-02542-2.